Data on Sanofi's multiple myeloma (MM) candidate isatuximab have gone down well at the American Society of Clinical Oncology meeting in Chicago but it remains to be seen whether it can compete with Johnson & Johnson's blockbuster and fellow anti-CD38 antibody Darzalex.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?